ISOPTO CETAMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOPTO CETAMIDE (ISOPTO CETAMIDE).
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
| Metabolism | Sulfacetamide is primarily metabolized in the liver via acetylation (N-acetyltransferase), and also undergoes glucuronidation and oxidation. |
| Excretion | Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination. |
| Half-life | Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 50-70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd ~0.3-0.5 L/kg, indicating moderate tissue penetration consistent with sulfonamide distribution. |
| Bioavailability | Ophthalmic: systemic absorption minimal (<10%) after topical administration; oral bioavailability of sulfacetamide is nearly 100% but not relevant for ophthalmic formulation. |
| Onset of Action | Ophthalmic: therapeutic effect within 1-2 hours after instillation for conjunctival bacterial infections. |
| Duration of Action | Ophthalmic: bacteriostatic concentrations maintained for 4-6 hours; requires frequent dosing (every 2-3 hours during waking hours). |
| Molecular Weight | 214.24 |
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No systemic absorption; no adjustment required. |
| Liver impairment | Not metabolized hepatically; no adjustment required. |
| Pediatric use | 1 drop into affected eye(s) every 2-3 hours initially, then reduce frequency based on response. Weight-based dosing not applicable; use same concentration as adults. |
| Geriatric use | No specific dose adjustment; monitor for local irritation and consider lower concentration (10%) if dry eye or reduced tear production. |
| 1st trimester | Avoid during first trimester unless benefit outweighs risk; sulfonamides may cause kernicterus in neonates when used near term, but theoretical risk of teratogenicity exists; no adequate well-controlled studies. |
| 2nd trimester | Use with caution; potential for neonatal jaundice and kernicterus if used near term. |
| 3rd trimester | Contraindicated near term (after 36 weeks) or in nursing mothers due to risk of kernicterus in neonates; sulfonamides displace bilirubin from albumin. |
Clinical note
Comprehensive clinical and safety monograph for ISOPTO CETAMIDE (ISOPTO CETAMIDE).
| Placental transfer | Sulfacetamide crosses the placenta; distributed to fetal tissues; potential for fetal toxicity and kernicterus. |
| Breastfeeding | Excreted in breast milk in small amounts; risk of kernicterus in neonates with G6PD deficiency or hyperbilirubinemia; avoid in breastfeeding mothers of infants with hyperbilirubinemia or G6PD deficiency. |
■ FDA Black Box Warning
None.
| Common Effects | Dry skin Increased liver enzymes Rash |
| Serious Effects |
Hypersensitivity to sulfonamides or any componentNursing mothers with infants who have hyperbilirubinemia or G6PD deficiencyUse near term (after 36 weeks gestation)
| Precautions | Hypersensitivity reactions may occur; cross-sensitivity with other sulfonamides is possible. Prolonged use may lead to overgrowth of nonsusceptible organisms including fungi. Discontinue if signs of local irritation or hypersensitivity develop. Patients with dry eye syndrome may experience increased irritation. |
| Food/Dietary | No known food interactions. Avoid excessive alcohol consumption as it may worsen ocular irritation. Maintain adequate hydration to support mucosal healing. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Isopto Cetamide (sulfacetamide sodium) is a sulfonamide antimicrobial. Sulfonamides are associated with an increased risk of kernicterus and hemolytic anemia in the fetus, particularly when administered near term. First trimester exposure may be associated with a small risk of congenital malformations, but data are limited. Second and third trimester use, especially in the last month, carries risk of neonatal jaundice and kernicterus due to bilirubin displacement from albumin. Avoid use after 36 weeks gestation or in labor. |
| Fetal Monitoring | Monitor maternal renal and hepatic function and complete blood cell count, especially with prolonged therapy. In the third trimester, assess fetal bilirubin levels if maternal administration is necessary. Observe neonates for signs of jaundice, hemolysis, or kernicterus if exposed near term. |
| Fertility Effects | No specific studies on effects of sulfacetamide on fertility. Sulfonamides have not been reported to impair fertility in humans; however, animal studies at high doses have shown some effects on spermatogenesis and ovarian function. Clinical relevance is uncertain. |
| Clinical Pearls | Isopto Cetamide (sulfacetamide sodium) is a topical ophthalmic sulfonamide antibiotic used for conjunctivitis and other superficial ocular infections. For optimal efficacy, instruct patient to shake the bottle well before instillation. Prolonged use may lead to bacterial resistance or fungal superinfection. Avoid use in patients with known sulfonamide hypersensitivity; systemic absorption can occur and cause severe reactions. Do not use in corneal epithelial defects or deep ocular infections as penetration is poor. Concurrent use with silver-containing products may cause discoloration. |
| Patient Advice | Shake the bottle well before each use. · Instill 1-2 drops into the affected eye(s) every 2-6 hours as prescribed. · Do not touch the dropper tip to any surface to avoid contamination. · Wash hands before and after administration. · Remove contact lenses before instillation; wait at least 15 minutes before reinserting. · Do not share this medication with others. · Complete full course even if symptoms improve. · Report any signs of allergic reaction (rash, itching, swelling) or persistent irritation immediately. · Store bottle upright at room temperature; discard after expiration or if solution becomes cloudy. |